Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NEPH 
Nephros Inc (NEPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NEPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.75
1 Year Target Price $4.75
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 113.26% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.36M USD | Price to earnings Ratio 51.12 | 1Y Target Price 4.75 |
Price to earnings Ratio 51.12 | 1Y Target Price 4.75 | ||
Volume (30-day avg) 2 | Beta 0.96 | 52 Weeks Range 1.36 - 5.00 | Updated Date 07/1/2025 |
52 Weeks Range 1.36 - 5.00 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.16% | Operating Margin (TTM) 11.61% |
Management Effectiveness
Return on Assets (TTM) 4.16% | Return on Equity (TTM) 9.17% |
Valuation
Trailing PE 51.12 | Forward PE - | Enterprise Value 40495428 | Price to Sales(TTM) 2.79 |
Enterprise Value 40495428 | Price to Sales(TTM) 2.79 | ||
Enterprise Value to Revenue 2.61 | Enterprise Value to EBITDA 42.23 | Shares Outstanding 10600400 | Shares Floating 9243611 |
Shares Outstanding 10600400 | Shares Floating 9243611 | ||
Percent Insiders 11.19 | Percent Institutions 44.02 |
Analyst Ratings
Rating 2 | Target Price 4.75 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nephros Inc
Company Overview
History and Background
Nephros, Inc. was founded in 1997. It initially focused on developing and commercializing improved hemodiafiltration (HDF) products for the treatment of patients with end-stage renal disease (ESRD). Over time, Nephros expanded its focus to include ultrafiltration technologies for infection control in hospitals and other healthcare facilities.
Core Business Areas
- Water Purification and Filtration: Develops and sells filters for use in dialysis centers for hemodialysis and hemodiafiltration, as well as filters used in hospitals for infection control and water purification.
Leadership and Structure
Nephros has a management team led by a Chief Executive Officer (CEO) and other key executives responsible for finance, operations, and sales. The company has a board of directors that provides oversight and guidance. Exact organizational structure details can be found in their public filings.
Top Products and Market Share
Key Offerings
- Hemodialysis Filters: Nephros' hemodialysis filters are used to remove waste and excess fluid from the blood of patients with kidney failure during hemodialysis. Market share data is not readily available, and precise revenue figures are not consistently reported. Competitors include major dialysis product manufacturers like Fresenius Medical Care (FMS) and DaVita (DVA) through their equipment segments as well as Asahi Kasei Medical.
- Ultrafilters for Infection Control: These filters are designed to remove bacteria, viruses, and endotoxins from water used in hospitals, helping to prevent healthcare-associated infections (HAIs). Market share data is not readily available. Competitors include Pall Corporation (part of Danaher) and several smaller companies specializing in water purification for healthcare.
Market Dynamics
Industry Overview
The market for dialysis products and infection control solutions is driven by the increasing prevalence of chronic kidney disease and the growing awareness of HAIs. It's a regulated market where product efficacy and safety are paramount.
Positioning
Nephros is a smaller player in a market dominated by larger, established companies. Its competitive advantage may lie in specialized filter technologies or specific niche applications within the broader dialysis and infection control markets.
Total Addressable Market (TAM)
The global dialysis market is estimated to be tens of billions of dollars. The infection control market is also substantial. Nephros' positioning hinges on capturing specific segments within these larger markets. TAM figures vary based on scope and assumptions.
Upturn SWOT Analysis
Strengths
- Proprietary filter technology
- Focus on niche markets
- Potential for innovation in water purification
Weaknesses
- Small market share compared to larger competitors
- Limited financial resources
- Dependence on regulatory approvals
Opportunities
- Expanding demand for dialysis products
- Growing concern about HAIs
- Potential for partnerships and collaborations
Threats
- Competition from larger, more established companies
- Changes in healthcare regulations
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- FMS
- DVA
- DHR
Competitive Landscape
Nephros faces intense competition from larger, well-established companies with greater resources and broader product portfolios. To compete effectively, Nephros must focus on innovation and niche market opportunities.
Growth Trajectory and Initiatives
Historical Growth: Nephros' historical growth has been varied, with periods of expansion and contraction depending on product sales and market conditions.
Future Projections: Future growth projections require analyst reports and company guidance, which are subject to change.
Recent Initiatives: Recent initiatives would include new product launches, partnerships, or strategic acquisitions. Reviewing press releases and investor presentations provides accurate details.
Summary
Nephros Inc. is a small company focusing on specialized filtration products in the dialysis and infection control markets. While they possess proprietary technology and target niche markets, they face significant competition from much larger companies. Their success depends on continuous innovation, strategic partnerships, and effective navigation of regulatory hurdles. They need to ensure they have sufficient finances to survive and expand.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Press Releases
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nephros Inc
Exchange NASDAQ | Headquaters South Orange, NJ, United States | ||
IPO Launch date 2004-09-21 | President, CEO & Director Mr. Robert Banks | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 31 | Website https://www.nephros.com |
Full time employees 31 | Website https://www.nephros.com | ||
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.